MFG
IRWD icon

Mendota Financial Group’s Ironwood Pharmaceuticals IRWD Stock Holding History

Mendota Financial Group’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11
Closed -$46 – 772
2024
Q3 		$46 Buy
+11
New +$59 ﹤0.01% 1150

Other funds holding IRWD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Mendota Financial Group's IRWD Position: Q4 2024 in Review

Mendota Financial Group sold out of Ironwood Pharmaceuticals (IRWD) in Q4 2024, closing a stake of 11 shares — an estimated $46 sold.

Mendota Financial Group first reported a position in IRWD in Q3 2024 and held it in 1 quarter. The position peaked at $46 in Q3 2024. 223 funds tracked by Wall St. Rank hold IRWD as of Q4 2024.

  • Mendota Financial Group reported no remaining Ironwood Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Mendota Financial Group sold 11 Ironwood Pharmaceuticals shares in Q4 2024, an estimated $46.
  • Mendota Financial Group first reported a position in Ironwood Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Mendota Financial Group's Ironwood Pharmaceuticals position peaked at $46 in Q3 2024.
  • 223 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q4 2024.

Based on Mendota Financial Group's 13F filing for Q4 2024, filed 14 Jan 2025.